Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia
Shots:
- Neurocrine has provided updates on the P-II (ERUDITE) trial assessing the safety & tolerability of luvadaxistat vs PBO to treat adults with cognitive impairment associated with schizophrenia (CIAS)
- The study did not reach its 1EP and failed to show similar cognitive endpoint results observed in INTERACT trial, likely due to high variability in cognitive measures & imbalances in baseline characteristics in treatment arms. INTERACT study showed significantly improved measure of cognition on the BACS & cognitive performance on the SCoRS
- Luvadaxistat (NBI-1065844) is an oral, selective DAAO inhibitor that targets D-Serine metabolism, a key NMDA receptor co-agonist. Neurocrine acquired its development rights from Takeda
Ref: Neurocrine Biosciences | Image: Neurocrine Biosciences
Related News:- Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
